ADMA Biologics Inc (ADMA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 5 Margin 4 Expansion 3 Platform 2 Financial 4

latest quarter score

Earnings Reports

18
ADMA (ADMA) Q2 2026: Ascentiv Grows 24% as Real-World Data Drives Prescriber Uptake
August 06, 2026
17
ADMA (ADMA) Q1 2026: Ascentive Grows 28% as Standard IG Downturn Triggers Guidance Reset
May 07, 2026
21
ADMA (ADMA) Q4 2025: Ascentive Drives 51% Growth, Margin Expansion Signals Durable Upside
February 26, 2026
22
ADMA (ADMA) Q3 2025: Yield-Enhanced Batches Lift Gross Margin to 63.7%, Powering 2026 Outlook
November 06, 2025
20
ADMA Biologics (ADMA) Q2 2025: Yield Enhancement Delivers 20% IG Output Gain, Margin Expansion in Focus
August 06, 2025
21
ADMA (ADMA) Q1 2025: Yield Enhancement Approval Unlocks 20% IG Output Surge, Margin Expansion Pathway
July 04, 2025
ADMA Biologics (ADMA) Q4 2024: 65% Revenue Growth Anchored by Expanded Plasma Supply and Yield Enhancement Prospects
March 04, 2025
ADMA (ADMA) Q3 2024: Ascentive Drives 78% Revenue Surge, Margin Expansion on Track for 2026
November 07, 2024
ADMA (ADMA) Q2 2024: Ascentive Surpasses 50% Revenue Mix, Yield Enhancement Targets 20% Output Gain
August 08, 2024
ADMA Biologics (ADMA) Q1 2024: EBITDA Soars 970% as Immunoglobulin Demand Drives Margin Expansion
May 09, 2024
20
ADMA (ADMA) Q4 2023: Gross Margin Jumps to 42% as Ascentive Uptake Accelerates
November 08, 2023
ADMA (ADMA) Q2 2023: Ascentive Mix Rises Toward 35%, Unlocking Margin Expansion Pathway
August 09, 2023
ADMA (ADMA) Q1 2023: 96% Revenue Surge Unlocks First-Time EBITDA Profitability, Margin Expansion Ahead
May 10, 2023
ADMA (ADMA) Q4 2022: 90% Revenue Surge Sets Up Margin Expansion and EBITDA Breakthrough
March 23, 2023

Browse all companies